Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(19):1422-1432; doi:10.1093/jnci/94.19.1422
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Canil, C. M.
Right arrow Articles by Tannock, I. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canil, C. M.
Right arrow Articles by Tannock, I. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 19, 1422-1432, October 2, 2002
© 2002 Oxford University Press

EDITORIAL

Should Bisphosphonates Be Used Routinely in Patients With Prostate Cancer Metastatic to Bone?

Christina M. Canil, Ian F. Tannock

Affiliation of authors: C. M. Canil, I. F. Tannock, Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada.

Correspondence to: Ian F. Tannock, M.D., Ph.D., Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, 610 University Ave., Toronto, Ontario M5G 2M9, Canada (e-mail: ian.tannock@uhn.on.ca).

The first 10% of the full text of this article appears below.

Prostate cancer is a disease that is characterized by a high incidence of metastases to bone, which cause substantial morbidity, including pain, fractures, and spinal cord compression. The primary modality of treatment for patients with metastatic prostate cancer is hormonal therapy, which is designed to reduce the stimulatory effects of androgens on prostate cancer cells. However, long-term use of androgen blockade has been shown to result in osteoporosis, which further contributes to bone fragility (1). Hormonal therapy to suppress serum testosterone levels is usually continued in patients with prostate cancer, even those with hormone-resistant prostate cancers. Treatment of patients with hormone-resistant prostate cancer has focused on palliation of symptoms and quality of life. Management of bone pain includes treatments with narcotic and anti-inflammatory medications, external beam radiation, bone-seeking radioactive . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha
Bone metastases from differentiated thyroid carcinoma
Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Joly and I. F. Tannock
Chemotherapy for patients with hormone-refractory prostate cancer
Ann. Onc., November 1, 2004; 15(11): 1582 - 1584.
[Full Text] [PDF]